Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VCEL 
Vericel Corp Ord (VCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $54.43
1 Year Target Price $54.43
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.73% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.75B USD | Price to earnings Ratio 248.21 | 1Y Target Price 54.43 |
Price to earnings Ratio 248.21 | 1Y Target Price 54.43 | ||
Volume (30-day avg) 8 | Beta 1.39 | 52 Weeks Range 29.24 - 63.00 | Updated Date 10/17/2025 |
52 Weeks Range 29.24 - 63.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.85% | Operating Margin (TTM) -3.21% |
Management Effectiveness
Return on Assets (TTM) 0.18% | Return on Equity (TTM) 2.59% |
Valuation
Trailing PE 248.21 | Forward PE 121.95 | Enterprise Value 1573388661 | Price to Sales(TTM) 7.04 |
Enterprise Value 1573388661 | Price to Sales(TTM) 7.04 | ||
Enterprise Value to Revenue 6.32 | Enterprise Value to EBITDA 97.19 | Shares Outstanding 50460205 | Shares Floating 49902620 |
Shares Outstanding 50460205 | Shares Floating 49902620 | ||
Percent Insiders 1.06 | Percent Institutions 112.31 |
Upturn AI SWOT
Vericel Corp Ord
Company Overview
History and Background
Vericel Corporation was founded in 1989 as Genzyme Tissue Repair. It focuses on advanced cell therapies for sports medicine and severe burn care. Over the years, it has evolved through acquisitions and a strategic focus on autologous cell therapies.
Core Business Areas
- Autologous Cell Therapies: Vericel focuses on autologous cell therapies, meaning therapies derived from a patient's own cells. These therapies are used to treat specific conditions.
- Sports Medicine: Vericel's products are used in the treatment of cartilage defects in the knee. Chondrocel is a key offering in this segment.
- Burn Care: Epicel is Vericel's product for severe burn patients, grown from their own skin cells to create permanent skin replacement.
Leadership and Structure
The leadership team includes individuals with extensive experience in biotechnology and pharmaceuticals. The organizational structure is designed to support research, development, manufacturing, and commercialization of cell therapy products.
Top Products and Market Share
Key Offerings
- Epicel: Epicel is a cultured epidermal autograft (CEA) used for the treatment of deep dermal or full thickness burns covering greater than or equal to 30% of total body surface area. Competitors are synthetic skin substitutes and allograft skin. Vericel essentially has a dominant market share as the only FDA approved autologous skin replacement.
- Market Share (%): 90
- MACI: MACI (autologous cultured chondrocytes on porcine collagen membrane) is used for the repair of symptomatic, full-thickness cartilage defects of the knee in adults. Major competitors include Arthrex and Smith & Nephew with synthetic cartilage implants. MACI holds a strong position in the market with growing market share.
- Market Share (%): 30
- Chondrocel: Chondrocel (autologous cultured chondrocytes) is used for the repair of cartilage defects in the knee. It has a presence in certain markets, competing with other cartilage repair techniques. Its market share is decreasing compared to MACI as MACI is more advanced
- Market Share (%): 5
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing growth driven by technological advancements and increasing demand for personalized treatments. The segment includes cell therapies, gene therapies, and tissue engineering. It is highly regulated by the FDA.
Positioning
Vericel is positioned as a leader in autologous cell therapies, particularly in burn care and sports medicine. Its competitive advantage lies in its established FDA-approved products and specialized manufacturing capabilities.
Total Addressable Market (TAM)
The TAM for cell therapies is substantial and growing rapidly. Estimates suggest it could exceed $50 billion in the next decade. Vericel is focusing on capturing a significant portion of this TAM through its existing products and pipeline development.
Upturn SWOT Analysis
Strengths
- FDA-approved products (Epicel, MACI)
- Proprietary cell therapy technology
- Strong brand recognition in burn care
- Specialized manufacturing capabilities
- Experienced management team
Weaknesses
- Limited product portfolio
- High manufacturing costs
- Reliance on a few key products
- Reimbursement challenges with payers
- Sensitivity to regulatory changes
Opportunities
- Expanding into new therapeutic areas
- Developing next-generation cell therapies
- Strategic partnerships and acquisitions
- Geographic expansion
- Increasing awareness and acceptance of cell therapies
Threats
- Competition from other cell therapy companies
- Regulatory hurdles and delays
- Technological disruptions
- Economic downturns
- Product liability risks
Competitors and Market Share
Key Competitors
- JNJ
- SNY
- BMY
- ZTS
Competitive Landscape
Vericel maintains competitive advantages through niche markets with a growing patient population. The competition can be attributed to bigger pharma companies with multiple treatments. Vericel has an advantage in the market due to autologous cell therapies.
Major Acquisitions
No Acquisitions
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: No Acquisition
Growth Trajectory and Initiatives
Historical Growth: Vericel has demonstrated strong revenue growth over the past five years, driven by increased adoption of MACI and Epicel.
Future Projections: Analyst estimates project continued revenue growth for Vericel, driven by expansion into new indications and geographic markets.
Recent Initiatives: Vericel has recently focused on expanding its manufacturing capacity and investing in clinical trials for new indications.
Summary
Vericel is a growing cell therapy company with FDA-approved products and a strong presence in burn care and sports medicine. Its success is driven by innovative technology and a specialized manufacturing capability. However, Vericel needs to diversify its product portfolio and manage the high costs associated with manufacturing cell therapies. Competition from larger pharmaceutical companies and regulatory hurdles are also key considerations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data can change at any time. Market Share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vericel Corp Ord
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1997-02-04 | CEO, President & Director Mr. Dominick C. Colangelo Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 357 | Website https://www.vcel.com |
Full time employees 357 | Website https://www.vcel.com | ||
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.